Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

AstraZeneca’s manufacturing will-they-won’t-they within its home country has swung back firmly toward the ‘they won’t’ camp ...

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...

After playing ball Wednesday during his first confirmation hearing with the Senate Finance Committee, Robert F. | Sens. Bill ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...

U.K.-based CDMO Upperton Pharma Solutions expanded its production footprint with the completion of a new £7 million ($8.1 ...

Although Lonza posted slightly lower sales than analysts had expected in 2024, the Swiss CDMO suggested in its year-end ...

Two attempts by Johnson & Johnson to resolve approximately 60,000 talcum powder lawsuits through bankruptcy courts have ...

The Trump administration’s executive order pausing foreign aid programs has sent crash waves through relief organizations ...